Mva-209-Fsp, Rp2D
Lynch Syndrome
National Cancer Institute (NCI)vaccinePhase 1/2Active
CCC
48/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 33/ 100
- Competitive Position
- 95/ 100
Competitive context
18 Active assets in the Lynch Syndrome cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Acetylsalicylic Acid M.D. Anderson Cancer Center | Phase 3 | BB |
Secretin Johns Hopkins University | Phase 3 | B |
Nivolumab National Cancer Institute (NCI) | Phase 2 | B |
Acetylsalicylic Acid Lysinate Assistance Publique - Hôpitaux de Paris | Phase 3 | B |
Atezolizumab National Cancer Institute (NCI) | Phase 3 | B |
View all 25 →
Same molecule, other indications
Mva-209-Fsp, Rp2D is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →